

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 November 2023 (23.11.2023)



(10) International Publication Number
WO 2023/225359 A1

- (51) **International Patent Classification:**
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2023/022990
- (22) **International Filing Date:**
19 May 2023 (19.05.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/344,510 20 May 2022 (20.05.2022) US
- (71) **Applicants:** **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). **LES LABORATOIRES SERVIER** [FR/FR]; 50, rue Carnot, 92284 Suresnes Cedex (FR).
- (72) **Inventor; and**
(71) **Applicant (for LC only):** **BURGER, Matthew, T.** [US/US]; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US).
- (72) **Inventors:** **CHEN, Zhuoliang**; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **D'ALESSIO, Joseph, Anthony**; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **HOLLINGWORTH, Gregory, John**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **KLINTER, Claudia, Judith**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **LANGLOIS, Jean-Baptiste**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **MCNEILL, Eric, Andrew**; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **MUNDT, Cornelia, Anne**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **NAKAJIMA, Katsumasa**; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **NEWCOMBE, Richard, Vaughan**; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **MADÖRIN, Katharina**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **YU, Bing**; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **ZHANG, Qiang**; c/o Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **FEJES, Imre**; Toboz utca 11, 3/13, 1037 Bu-

dapest (HU). **GENESTE, Olivier**; 60 rue du General Carrey de Bellemare, 92500 Rueil-Malmaison (FR). **MARAGNO, Ana, Leticia**; 10 Allée des Jardins, 78112 Saint-Germain En Laye (FR). **RAY, Stuart**; 10 Groves Way, Cottenham, Cambs CB24 8BH (GB). **ROCCHETTI, Francesca**; Webgasse 37/2/15, 1060 Vienna (AT). **STARCK, Jérôme, Benoît**; 36 rue Favre d'Eglantine, 92500 Rueil-Malmaison (FR). **SZLAVIK, Zoltan**; Pilisi ufc 3, 2000 Szentendre (HU).

(74) **Agent:** **ZHANG, Xin** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF

(57) **Abstract:** Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an antibody or an antigen-binding fragment thereof covalently linked to two antineoplastic payloads through a dual linker, wherein at least one antineoplastic payload is a BH3 mimetic. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising at least one BH3 mimetic and methods of making the same are also disclosed.



WO 2023/225359 A1